GLP1R and type 2 diabetes mellitus: With regard to the direct nephroprotective effects of GLP1-RA, the available data have so far mostly been extrapolated from studies with primary cardiovascular (CV) outcomes [15, 16], but very recently, the FLOW trial reported a clear benefit of semaglutide on renal outcomes and death from CV causes in patients with T2D and CKD [17].